<DOC>
	<DOCNO>NCT02486510</DOCNO>
	<brief_summary>Effect HIV-1 cell reservoir concomitant administration intensive chemotherapy pharmacological blockade CCR5 coreceptors : pilot , open , randomize , control clinical trial .</brief_summary>
	<brief_title>Effect Cytoreductive Chemotherapy CCR5 Coreceptor Antagonist HIV-1 Eradication</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Patients give write consent participate study Age 18 65 year old , include . Chronic HIV1 Demonstration R5 viral tropism ( use CCR5 coreceptors ) genotyping plasma sample store Patients treated intensive chemotherapy non Hodgkin lymphoma With without stable antiretroviral therapy Patients able understand purpose study available schedule appointment . Both case female male patient , patient agrees use double barrier method contraception moment signing inform consent 3 month end participation study . To planned antiretroviral treatment interruption participation study Hypersensitivity product use study To involve another clinical trial receive investigational drug within 3 month prior study initiation To contraindication limitation perform leukapheresis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>CCR5 coreceptors</keyword>
	<keyword>Maraviroc</keyword>
</DOC>